Myelin injury precedes axonal injury and symptomatic onset in multiple sclerosis
Top Cited Papers
- 20 October 2025
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 32 (1) , 362-368
Abstract
The timing of the biological onset of multiple sclerosis (MS) is unclear. We used high-throughput discovery proteomics and samples from presymptomatic patients with MS and matched healthy controls to define the biological neurological onset and characterize the mechanisms involved. Remarkably, evidence of myelin injury was seen ~7 years before the symptomatic onset and preceded evidence of axonal injury by ~1 year. By contrast, astrocyte involvement became evident only at clinical onset. Numerous changes in the serum proteome indicate the involvement of interleukin 3 and nuclear factor kappa B pathways during the presymptomatic stage. Furthermore, people with MS with a previously reported distinct autoantibody signature showed increased immune cell activity compared to those without. We propose a protein biomarker panel that may help distinguish presymptomatic patients with MS from healthy controls, pending validation in future studies. Our findings can help understand the pathophysiology of MS as well as the cascade of central nervous system injury and might facilitate early detection of MS in high-risk people.Keywords
Funding Information
- U.S. Department of War (HT94252310499)
- National Multiple Sclerosis Society
- Valhalla Foundation, Westridge Foundation, Water Cove Charitable Foundation
- Valhalla Foundation, Westridge Foundation
This publication has 38 references indexed in Scilit:
- Plasma proteomic profiles of UK Biobank participants with multiple sclerosisAnnals of Clinical and Translational Neurology, 2024
- Interleukin-3 coordinates glial-peripheral immune crosstalk to incite multiple sclerosisImmunity, 2023
- Stability and reproducibility of proteomic profiles in epidemiological studies: comparing the Olink and SOMAscan platformsProteomics, 2022
- Radiologically Isolated Syndrome:10‐YearRisk Estimate of a Clinical EventAnnals of Neurology, 2020
- Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple SclerosisJAMA Neurology, 2020
- Toward understanding the origin and evolution of cellular organismsProtein Science, 2019
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteriaThe Lancet Neurology, 2018
- Preclinical disease activity in multiple sclerosis: A prospective study of cognitive performance prior to first symptomAnnals of Neurology, 2016
- Nuclear factor kappa B (NF-κB) in multiple sclerosis pathologyTrends in Molecular Medicine, 2013
- The changing demographic pattern of multiple sclerosis epidemiologyThe Lancet Neurology, 2010